Loading
A phase 1/2 trial of GTAEXS617 in head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, non-small-cell lung cancer, ovarian cancer, HR-positive / HER2-negative breast cancer and triple-negative breast cancer, run by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc., now recruiting.
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05985655 by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc., with 230 participants planned, started 2023-07-06 and due to reach its primary completion in 2028-01. Interventions recorded: GTAEXS617 and SoC.
Shares Head and neck squamous cell carcinoma, Ovarian cancer, Triple-negative breast cancer (TNBC), Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Triple-negative breast cancer (TNBC), Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Ovarian cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Recursion Pharmaceuticals and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.